Candel Therapeutics, Inc. short interest in 2026
In 2026, Candel Therapeutics, Inc.'s disclosed short interest ran from 16.98% of shares outstanding on 15 Jan 2026 to 16.13% on 15 Sep 2026, a change of -0.85 percentage points. The year's high was 23.65% on 27 Feb 2026 and its low 16.03% on 31 Aug 2026, averaging 18.70% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.91 days on 13 Feb 2026. Full history: Candel Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 16.98% (15 Jan 2026)
- End of year
- 16.13% (15 Sep 2026)
- Change
- -0.85 pp
- High
- 23.65% (27 Feb 2026)
- Low
- 16.03% (31 Aug 2026)
- Average
- 18.70%
- Highest days to cover
- 15.91 (13 Feb 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 16.98% | 12.97 | |
| 30 Jan 2026 | 17.04% | 12.59 | |
| 13 Feb 2026 | 16.93% | 15.91 | |
| 27 Feb 2026 | 23.65% | 6.76 | results (8-K) |
| 13 Mar 2026 | 19.36% | 11.12 | 10-K filed, results (8-K) |
| 31 Mar 2026 | 20.23% | 11.71 | |
| 15 Apr 2026 | 20.57% | 15.51 | |
| 30 Apr 2026 | 20.04% | 6.41 | |
| 15 May 2026 | 19.69% | 5.54 | 10-Q filed, results (8-K) |
| 29 May 2026 | 19.34% | 7.64 | |
| 15 Jun 2026 | 18.59% | 7.58 | |
| 30 Jun 2026 | 22.03% | 5.98 | |
| 15 Jul 2026 | 17.70% | 9.01 | |
| 31 Jul 2026 | 17.28% | 10.41 | |
| 14 Aug 2026 | 16.29% | 10.56 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 16.03% | 9.19 | |
| 15 Sep 2026 | 16.13% | 10.28 |
See also: Candel Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.